10 Years of Catapult Solutions Group

Since 2013, Catapult Solutions Group has strived to be the very best staffing firm it can be. While it started out small, it has since grown to become a top staffing firm, winning multiple awards between 2021 and 2022, including being named one of the fastest growing firms in the USA.

On this episode of Hire Education, to celebrate ten years of Catapult Solutions Group, CEO & Founder Patrick Burke sat down with two of his co-workers—Chief Delivery Office Mitch Blackwell and VP of Delivery (as well as Founder) Chris Burke—to talk about this monumental achievement for the company. Patrick begins by saying “Chris and I, and a bunch of others, wanted to start our own company and do it our way” before going into the story of how the company came to be in San Antonio, TX. While it took some time to nail down what exactly they wanted to focus on, they eventually got there, becoming bigger than they ever expected to be.

The trio also discuss:

  1.  The difficulty of starting a new business (and keeping the lights on).
  2. Stories of moments and events that occurred in those first ten years.
  3. The many employees who have come and gone.

While spending a lot of time telling stories, Chris also wants to make clear just how much has changed in the last decade, and how large Catapult Solutions Group has become. “What I realize today sitting here…it’s bigger than all of us,” says Patrick. This is bigger than Chris, and Mitch, and myself. There’s a huge company out there with seventy-five to a hundred employees we have, we have people intentionally in Europe, and so it feels really good to see something that’s much bigger than who we are.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More